Clinical Trial Update: T790M Mutation Positive 2nd Line STandard of cAre Registry

View source ↗

Summary

ClinicalTrials.gov entry for a T790M mutation-positive, second-line standard of care registry in non-small cell lung cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Status: WITHDRAWN